Susan Hasty, Publisher
Table of Contents . . . September 22nd, 2000
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Drug Week | Other Publications
Congestive Heart Failure - Novel Cardiovascular Drug Target Discovered
Arthritis - Treatment with Celecoxib Has Fewer Adverse Effects than NSAIDS
Asthma - Experimental Monoclonal Antibody Could Help Patients with Refractory Disease
Asthma - Steroid Pills Prove Superior to Inhaled Version
Chronic Obstructive Pulmonary Disease - Anti-Smoking Pill Effective Against COPD
Chronic Obstructive Pulmonary Disease - New Drug Tested For 'Smoker's Lung'
Drug Safety - Blood of Horseshoe Crabs a Medical Miracle
Adverse Drug Effects - Long-Term Tamoxifen Users Have Worse Prognosis of Endometrial Cancers
Analgesia - Liposome Encapsulation Extends Duration of Morphine Pain Relief
Anaplastic Thyroid Carcinoma - Newly-Discovered Drug Prolongs Survival in Some Patients with Rare Cancer
Antibiotic Resistance - CDC Survey Shows Doctors Are Getting the Message: Go Easy on Antibiotics
Arthritis - NO-Naproxen Reduces Pain, Inflammation
Barrett's Esophagus - Photofrin Phase III Trial Results Confirm Treatment Efficacy
Cancer Therapies - Fungal Metabolite Cytochalasin E Exhibits Anti-Tumor Properties in Mouse Model
Candida albicans - Essential Gene Identification Completed
Fabry Disease - Confidence Expressed in Fabrazyme Data
Hypertension - FDA Approves Second-Line Treatment
Insomnia - (S)-Zopiclone Advances to Phase III Studies
Legal Issues - Couple Jailed for Falsifying Drug Results
Patent Litigation - Judge Rules Against Bristol-Myers
Regulatory Issues - FDA Cracks Down on Laetrile Resurgence
Respiratory Syncytial Virus - New Compound is Effective Against RSV in Lab Experiments
Therapy (HCV) - Companies Will Co-Develop Hepatitis C Drugs
Type 2 Diabetes - Acarbose Can Increase Insulin Sensitivity in Older Patients
Type 2 Diabetes - Bromocriptine Can Increase Glucose Tolerance
Venous Thromboembolism - Events Prevented with Pentasaccharide
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.